OXUR Stock Overview
A biopharmaceutical company, develops medicines to prevent blindness. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Oxurion NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.32 |
| 52 Week High | €6.00 |
| 52 Week Low | €0.28 |
| Beta | 0.58 |
| 11 Month Change | 10.15% |
| 3 Month Change | -68.00% |
| 1 Year Change | -96.44% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
What Type Of Returns Would Oxurion's(EBR:OXUR) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Feb 01
How Is Oxurion's (EBR:OXUR) CEO Compensated?
Dec 09
Here's What We Learned About The CEO Pay At Oxurion NV (EBR:OXUR)
Aug 20Oxurion (EBR:OXUR) Share Prices Have Dropped 43% In The Last Year
Jul 17Shareholder Returns
| OXUR | BE Biotechs | BE Market | |
|---|---|---|---|
| 7D | 9.8% | 2.9% | 0.7% |
| 1Y | -96.4% | 5.3% | 3.0% |
Return vs Industry: OXUR underperformed the Belgian Biotechs industry which returned 5.3% over the past year.
Return vs Market: OXUR underperformed the Belgian Market which returned 3% over the past year.
Price Volatility
| OXUR volatility | |
|---|---|
| OXUR Average Weekly Movement | 32.7% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in BE Market | 6.4% |
| 10% least volatile stocks in BE Market | 2.3% |
Stable Share Price: OXUR's share price has been volatile over the past 3 months compared to the Belgian market.
Volatility Over Time: OXUR's weekly volatility has decreased from 59% to 33% over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 20 | Pascal Ghoson | www.oxurion.com |
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018.
Oxurion NV Fundamentals Summary
| OXUR fundamental statistics | |
|---|---|
| Market cap | €427.60k |
| Earnings (TTM) | -€11.37m |
| Revenue (TTM) | €84.00k |
5.1x
P/S Ratio0.0x
P/E RatioIs OXUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OXUR income statement (TTM) | |
|---|---|
| Revenue | €84.00k |
| Cost of Revenue | €105.00k |
| Gross Profit | -€21.00k |
| Other Expenses | €11.35m |
| Earnings | -€11.37m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.51 |
| Gross Margin | -25.00% |
| Net Profit Margin | -13,539.29% |
| Debt/Equity Ratio | -78.8% |
How did OXUR perform over the long term?
See historical performance and comparison